Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry

References

• Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis. EMA/CPMP/EWP/4891/03 Rev.1 2017; [cited 2019 Nov]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-axial-spondyloarthritis-revision-1_en.pdf
   Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015. DOI:10.1002/14651858.CD005468.pub2.
   Web of Science ®Google Scholar
• Yang X, Fan D, Xia Q, et al. The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. Qual Life Res. 2016;25:2711–2723.
   PubMed Web of Science ®Google Scholar
• Mlcoch T, Sedova L, Stolfa J, et al. Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Rev Pharmacoecon Outcomes Res. 2017;17:203–211.
   PubMed Web of Science ®Google Scholar
• Ward MM, Weisman MH, Davis JC, et al. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum. 2005;53:710–717.
   PubMed Web of Science ®Google Scholar
• Boonen A, Brinkhuizen T, Landewe R, et al. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis. 2010;69:1123–1128.
   PubMed Web of Science ®Google Scholar
• Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol. 2006;2:546–553.
   PubMedGoogle Scholar
• Kucharz EJ, Kotulska A, Kopeć-Mędrek M, et al. Opinion of patients with ankylosing spondylitis on risk factors impairing their quality of life. Rheumatol Int. 2013;33:2899–2901.
   PubMed Web of Science ®Google Scholar
• Rodrigues Manica S, Sepriano A, Ramiro S, et al. Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. Ann Rheum Dis. 2018;77:1303–1310.
   PubMed Web of Science ®Google Scholar
• Chorus AMJ. Employment perspectives of patients with ankylosing spondylitis. Ann Rheum Dis. 2002;61:693–699.
   PubMed Web of Science ®Google Scholar
• Cooksey R, Husain MJ, Brophy S, et al. The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data. Plos One. 2015;10:e0126105.
   PubMed Web of Science ®Google Scholar
• Petříková A, Doležal T, Klimeš J, et al. The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Rheumatol Int. 2013;33:1813–1819.
   PubMed Web of Science ®Google Scholar
• Kruntorádová K, Klimeš J, Šedová L, et al. Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value Health Reg Issues. 2014;4:100–106.
   PubMedGoogle Scholar
• Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3–17.
   PubMed Web of Science ®Google Scholar
• Sağ S, Nas K, Sağ MS, et al. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis. J Back Musculoskelet Rehabil. 2018;31:499–505.
   PubMed Web of Science ®Google Scholar
• Druce KL, Aikman L, Dilleen M, et al. Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients. Arthritis Res Ther. 2018. DOI:10.1186/s13075-018-1598-8.
   PubMed Web of Science ®Google Scholar
• Shim J, Jones GT, Pathan EMI, et al. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis. Ann Rheum Dis Annrheumdis. 2018. DOI:10.1136/annrheumdis-2018-213590
   PubMed Web of Science ®Google Scholar
• Cakar E, Taskaynatan MA, Dincer U, et al. Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol. 2009;28:1309–1314.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–991.
   PubMed Web of Science ®Google Scholar
• Mann H, Bubová K, Závada J, et al. SAT0285 Efficacy of early versus delayed initiation of anti-TNF-alpha treatment in axial spondyloarthritis. Data from the Czech Registry Attra Ann Rheum Dis. 2018;77:1006.
   Web of Science ®Google Scholar
• Landewé R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392:134–144.
   PubMed Web of Science ®Google Scholar
• Zong H, Xu S, Tong H, et al. Effect of anti-tumor necrosis factor α treatment on radiographic progression in patient with ankylosing spondylitis: a systematic review and meta-analysis. Mod Rheumatol. 2019;29(3):503–509.
   Web of Science ®Google Scholar
• Zavada J, Szczukova L, Pavelka K, et al. THU0650 The effect of anti-TNF therapy on work productivity and activity impairment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over one year – real life data from the czech biologics registry attra. Ann Rheum Dis. 2017;76:451–452.
   Web of Science ®Google Scholar
• Stolwijk C, J-D C, Gignac M, et al. Importance of contextual factors when measuring work outcome in ankylosing spondylitis: a systematic review by the OMERACT worker productivity group. Arthritis Care Res. 2015;67:1316–1327.
   Web of Science ®Google Scholar
• Ariza-Ariza R, Hernández-Cruz B, Collantes E, et al. Work disability in patients with ankylosing spondylitis. J Rheumatol. 2009;36:2512–2516.
   PubMed Web of Science ®Google Scholar
• Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol. 2001;28:315–321.
   PubMed Web of Science ®Google Scholar
• Bakland G, Gran JT, Becker-Merok A, et al. Work Disability in Patients with Ankylosing Spondylitis in Norway. J Rheumatol. 2011;38:479–484.
   PubMed Web of Science ®Google Scholar
• Molto A, Gossec L, Meghnathi B, et al. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis. 2018;77:124–127.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286–2291.
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18–24.
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55.
   PubMed Web of Science ®Google Scholar
• I Fernandez AS, Juanola Roura X, Alonso Ruiz A, et al. Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (axis study). Rheumatol Int. 2017;37:1817–1823.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Zavada J, Kristkova Z, et al. FRI0122 drug survival of adalimumab in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis over 10 years in real-world setting of czech registry attra. Ann Rheum Dis. 2018;77:605–606.
   Google Scholar
• Dixon WG, Carmona L, Finckh A, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis. 2010;69:1596–1602.
   PubMed Web of Science ®Google Scholar
• Machado PMMC, Landewe RBM, van der HEIJDE DM. Endorsement of definitions of disease activity states and improvement scores for the ankylosing spondylitis disease activity score: results from OMERACT 10. J Rheumatol. 2011;38:1502–1506.
   PubMed Web of Science ®Google Scholar
• Pavelka K. Doporučení České revmatologické společnosti pro léčbu ankylozující spondylitidy. Czech Rheumatology/Ceska Revmatologie. 2012;20(1):4–11.
   Google Scholar
• TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis; Technology appraisal guidance [TA383], NICE 2016
   Google Scholar
• Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47–53.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–365.
   PubMed Web of Science ®Google Scholar
• van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69:i89–i91.
   PubMed Web of Science ®Google Scholar
• Newson R. Comparing the predictive powers of survival models using Harrell’s C or Somers’ D. Stata J. 2010;10:339–358.
   Web of Science ®Google Scholar
• Mlcoch T, Tuzil J, Stolfa J, et al. The relationship between biological therapy, work productivity, and activity impairment in patients with psoriatic arthritis: prospective multicentre observational study. Arthritis Rheumatol. 2017; 69 (suppl 10); [cited 2019 Nov]. Available from: https://acrabstracts.org/abstract/the-relationship-between-biological-therapy-work-productivity-and-activity-impairment-in-patients-with-psoriatic-arthritis-prospective-multicentre-observational-study/
   Web of Science ®Google Scholar
• Raudenbush SW, Bryk AS. Hierarchical linear models: applications and data analysis methods. 2nd ed. Thousand Oaks: Sage Publications; 2002.
   Google Scholar
• Mlcoch T, Tuzil J, Sedova L, et al. Mapping quality of life (EQ-5D) from DAPsA, clinical DAPsA and HAQ in Psoriatic Arthritis. Patient - Patient-Centered Outcomes Res. 2018;11:329–340.
   Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–349.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Smeeth L, Guttmann A, et al. The reporting of studies conducted using observational routinely-collected health data (RECORD) Statement. PLOS Med. 2015;12:e1001885.
   PubMed Web of Science ®Google Scholar
• Webers C, Ramiro S, Landewé R, et al. Sick leave and its predictors in ankylosing spondylitis: long-term results from the outcome in ankylosing spondylitis international study. RMD Open. 2018;4:e000766.
   PubMed Web of Science ®Google Scholar
• Boonen A. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis. 2001;60:1033–1039.
   PubMed Web of Science ®Google Scholar
• Chen C-H, Chen H-A, Liao H-T, et al. The clinical usefulness of ESR, CRP, and disease duration in ankylosing spondylitis: the product of these acute-phase reactants and disease duration is associated with patient’s poor physical mobility, CHMP,2018. Rheumatol Int. 2015;35:1263–1267.
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Knight EL, Levin R, et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiol Camb Mass. 2001;12:682–689.
   PubMed Web of Science ®Google Scholar
• Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4–11.
   PubMedGoogle Scholar
• Boonen A, Boone C, Albert A, et al. Contextual factors influence work outcomes in employed patients with ankylosing spondylitis starting etanercept: 2-year results from AS@Work. Rheumatology. 2018;57:791–797.
   PubMed Web of Science ®Google Scholar